A Phase 3 interventional study of Gemcitabine and Paclitaxel in Genital Neoplasms, Female, Fallopian Tube Neoplasms and Ovarian Neoplasms, sponsored by Eli Lilly and Company. Completed at 55 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2002, is one of 2 in phase 3, and was the 2nd registered.
81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.
Browse Genital Neoplasms, Female studies →6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Women only
Corcept Therapeutics · Sites in United States, Belgium, France and 5 more countries
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Women only
Marengo Therapeutics, Inc. · Sites in United States, Canada, France and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 2
First in 1999; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 919 is above the median of 78 across 63 interventional studies indexed under Genital Neoplasms, Female.
Median enrollment 40 across the 33 interventional studies, 750 across the 4 observational. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 37 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 4 studies filed under Genital Neoplasms, Female — fewer than ten, so there is no comparison to draw.
6 of the studies in Genital Neoplasms, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05979610University of UtahUsing Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT03141437M.D. Anderson Cancer CenterDecision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer | 2027-04-30 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
| NCT05053230Memorial Sloan Kettering Cancer CenterA Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer | 2027-09-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.
This study (Study B9E-US-S302) is a multicenter, comparative, open-label randomized, superiority, trial evaluating Gemcitabine and Carboplatin to the standard of care. Both treatment arms will be given the option to receive elective consolidation therapy of Paclitaxel 135 mg/m\^2 given every 28 days for one year. Patients not achieving a complete response will crossover to the opposite single agent.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine 1000 milligrams per meter square (mg/m\^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
Drug: Gemcitabine · Drug: Carboplatin
Paclitaxel 175 milligrams per meter square (mg/m\^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
Drug: Paclitaxel · Drug: Carboplatin
1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity
Also known as: LY188011, Gemzar
175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year) If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity
Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles
Progression Free Survival (PFS)
Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
Time frame: Baseline to measured progressive disease or death up to 82 months
Proportion of Participants With Response (Response Rate)
Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions \[TL\]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).
Time frame: Baseline to measured progressive disease up to 82 months
Time to Treatment Failure
Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
Time frame: Baseline to stopping treatment up to 82 months
Overall Survival
Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
Time frame: Baseline to death from any cause up to 82 months
| Milestone | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin |
|---|---|---|
| Started | 417 | 414 |
| Received induction therapy | 411 | 409 |
| Received consolidation therapy | 169 | 183 |
| Received crossover therapy | 77 | 78 |
| Completed | 246 | 261 |
| Not completed | 171 | 153 |
| Withdrew: Toxicity | 26 | 37 |
| Withdrew: Disease progression | 5 | 6 |
| Withdrew: Physician decision | 20 | 11 |
| Withdrew: Withdrawal by subject | 58 | 39 |
| Withdrew: Protocol violation | 5 | 7 |
| Withdrew: Death | 6 | 8 |
| Withdrew: Other | 33 | 34 |
| Withdrew: Missing data | 18 | 11 |
Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
| Months | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin |
|---|---|---|
| Progression Free Survival (PFS) | 20.0 (17.9 to 22.2) | 22.2 (19.0 to 25.7) |
Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions \[TL\]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).
| proportion of responders | Gemcitabine/Carboplatin (Induction) | Paclitaxel/Carboplatin (Induction) | Gemcitabine (Crossover) | Paclitaxel (Crossover) |
|---|---|---|---|---|
| Proportion of Participants With Response (Response Rate) | 0.676 (0.638 to 0.798) | 0.711 (0.651 to 0.822) | 0.357 (0.194 to 0.576) | 0.303 (0.161 to 0.500) |
Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
| months | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin |
|---|---|---|
| Time to Treatment Failure | 13.0 (11.7 to 15.1) | 13.1 (11.4 to 14.3) |
Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.
| months | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin |
|---|---|---|
| Overall Survival | 43.8 (38.8 to 48.4) | 57.3 (48.5 to 64.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine/Carboplatin Induction | — | 96/412 (23.3%) | 404/412 (98.1%) |
| Paclitaxel/Carboplatin Induction | — | 72/408 (17.6%) | 394/408 (96.6%) |
| Consolidation (Gemcitabine to Paclitaxel) | — | 14/169 (8.3%) | 157/169 (92.9%) |
| Consolidation (Paclitaxel to Paclitaxel) | — | 12/183 (6.6%) | 170/183 (92.9%) |
| Crossover (Paclitaxel to Gemcitabine) | — | 8/78 (10.3%) | 76/78 (97.4%) |
| Crossover (Gemcitabine to Paclitaxel) | — | 8/77 (10.4%) | 73/77 (94.8%) |
| Event | Gemcitabine/Carboplatin Induction | Paclitaxel/Carboplatin Induction | Consolidation (Gemcitabine to Paclitaxel) | Consolidation (Paclitaxel to Paclitaxel) | Crossover (Paclitaxel to Gemcitabine) | Crossover (Gemcitabine to Paclitaxel) |
|---|---|---|---|---|---|---|
| PlateletsInvestigations | 43/412 | 5/408 | 0/169 | 0/183 | 0/78 | 0/77 |
| HemoglobinInvestigations | 24/412 | 3/408 | 0/169 | 0/183 | 1/78 | 0/77 |
| Absolute neutrophil count/absolute granulocyte countInvestigations | 21/412 | 14/408 | 1/169 | 1/183 | 1/78 | 0/77 |
| NauseaGastrointestinal disorders | 12/412 | 8/408 | 0/169 | 0/183 | 0/78 | 0/77 |
| PyrexiaGeneral disorders | 8/412 | 2/408 | 0/169 | 0/183 | 2/78 | 1/77 |
| VomitingGastrointestinal disorders | 10/412 | 9/408 | 1/169 | 0/183 | 1/78 | 0/77 |
| White blood cellsInvestigations | 10/412 | 3/408 | 0/169 | 1/183 | 0/78 | 0/77 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/412 | 9/408 | 0/169 | 0/183 | 1/78 | 1/77 |
| DehydrationMetabolism and nutrition disorders | 6/412 | 7/408 | 0/169 | 0/183 | 1/78 | 0/77 |
| Abdominal painGastrointestinal disorders | 6/412 | 5/408 | 1/169 | 2/183 | 0/78 | 0/77 |
| Event | Gemcitabine/Carboplatin Induction | Paclitaxel/Carboplatin Induction | Consolidation (Gemcitabine to Paclitaxel) | Consolidation (Paclitaxel to Paclitaxel) | Crossover (Paclitaxel to Gemcitabine) | Crossover (Gemcitabine to Paclitaxel) |
|---|---|---|---|---|---|---|
| HemoglobinInvestigations | 385/412 | 352/408 | 83/169 | 103/183 | 66/78 | 54/77 |
| White blood cellsInvestigations | 380/412 | 350/408 | 88/169 | 101/183 | 68/78 | 49/77 |
| PlateletsInvestigations | 379/412 | 233/408 | 36/169 | 23/183 | 61/78 | 16/77 |
| Anc/agcInvestigations | 378/412 | 361/408 | 88/169 | 93/183 | 68/78 | 47/77 |
| FatigueGeneral disorders | 281/412 | 279/408 | 108/169 | 119/183 | 56/78 | 40/77 |
| AlopeciaSkin and subcutaneous tissue disorders | 94/412 | 249/408 | 102/169 | 94/183 | 42/78 | 49/77 |
| NauseaGastrointestinal disorders | 213/412 | 205/408 | 67/169 | 46/183 | 32/78 | 21/77 |
| ConstipationGastrointestinal disorders | 173/412 | 170/408 | 54/169 | 62/183 | 31/78 | 25/77 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 48/412 | 108/408 | 66/169 | 53/183 | 16/78 | 25/77 |
| Neuropathy peripheralNervous system disorders | 22/412 | 99/408 | 62/169 | 68/183 | 17/78 | 23/77 |
| Age Continuous(years) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Mean | 59.7 ± 11.4 | 60.3 ± 10.8 | 60.0 ± 11.1 |
| Sex: Female, Male(Participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Female | 417 | 414 | 831 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Caucasian | 379 | 379 | 758 |
| Black or African American | 12 | 13 | 25 |
| Asian | 5 | 5 | 10 |
| Native American | 2 | 1 | 3 |
| Other | 19 | 16 | 35 |
| Organ of Origin(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Ovary | 355 | 362 | 717 |
| Peritoneum | 56 | 50 | 106 |
| Missing Data | 6 | 2 | 8 |
| Extent of Residual Disease(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Measurable | 139 | 114 | 253 |
| Non-measurable | 276 | 300 | 576 |
| Missing Data | 2 | 0 | 2 |
| Zubrod Performance Status(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| 0 | 239 | 232 | 471 |
| 1 | 139 | 157 | 296 |
| 2 | 27 | 16 | 43 |
| >= 3 | 0 | 0 | 0 |
| Missing Data | 12 | 9 | 21 |
| International Federation of Gynecology and Obstetrics (FIGO) Stage at Initial Surgery(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Stage Ic | 21 | 22 | 43 |
| Stage II | 44 | 39 | 83 |
| Stage III | 284 | 289 | 573 |
| Stage IV | 68 | 63 | 131 |
| Missing Data | 0 | 1 | 1 |
| Histology(participants) | Gemcitabine/Carboplatin | Paclitaxel/Carboplatin | Total |
|---|---|---|---|
| Mucinous | 10 | 10 | 20 |
| Serous | 283 | 276 | 559 |
| Endometroid | 44 | 40 | 84 |
| Undifferentiated | 7 | 7 | 14 |
| Clear Cell | 21 | 23 | 44 |
| Mixed Epithelial | 9 | 13 | 22 |
| Transitional Cell | 3 | 1 | 4 |
| Malignant Brenner's Tumor | 0 | 0 | 0 |
| Adenocarcinoma Not Otherwise Specified (NOS) | 22 | 23 | 45 |
| Other | 17 | 21 | 38 |
| Missing Data | 1 | 0 | 1 |
2 further baseline measures are reported on the registry.
The record gives a start of Oct 2002, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine